PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20180202 160137
20180814 193547
20170731 010044
20180202 161620
DJI 0025
IMG-20170807-WA0033
  • OPDP eCTD
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-20 By FDA
  • Compounding Quality Center of Excellence | Engage with the Compounding Quality Center of Excellence
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-20 By FDA
  • GDUFA Type II API DMF Payment Receipts Report
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-20 By FDA
  • Pediatric Tracking Requirements Under FDAAA
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-20 By FDA
  • Human medicines European public assessment report (EPAR): Afinitor, everolimus, Date of authorisation: 02/08/2009, Revision: 33, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Human medicines European public assessment report (EPAR): Votubia, everolimus, Date of authorisation: 02/09/2011, Revision: 34, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Competitive Generic Therapy Approvals
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-20 By FDA
  • Human medicines European public assessment report (EPAR): Maviret, glecaprevir,pibrentasvir, Date of authorisation: 26/07/2017, Revision: 23, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 15, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Date of authorisation: 19/02/2015, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Human medicines European public assessment report (EPAR): Atectura Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Human medicines European public assessment report (EPAR): Enerzair Breezhaler, indacaterol,glycopyrronium bromide,mometasone, Date of authorisation: 03/07/2020, Revision: 11, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
  • Executive Order 14017 on America’s Supply Chains
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-20 By FDA
  • Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Date of authorisation: 17/11/2025, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-20
Older posts
Theme: Scaffold by Danny Cooper.